Oncology

Bayer and Orion's Nubeqa gets FDA recommendations for Prostate Cancer The U.S. FDA has given its nod to Nubeqa (darolutamide) for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). Nubeqa is a steroidal androgen receptor inhibitor (ARi), and its recommendation came after its positive results in Phase III ARAMIS trial plus androgen deprivation therapy (ADT) compared to placebo plus ADT. Nubeqa, the co-product of Bayer and Orion received the approval under the FDA Priority Review designation. The drug is set to join other anti-androgens already available in the Prostate cancer therapy market such as Abiraterone and Bicalutam...